ClinicalTrials.gg
RecruitingNCT07327034Updated Jan 8, 2026

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

A Phase 2 interventional study of ABSK-011+BSC and Placebo+BSC in Hepatocellular Carcinoma (HCC), sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
350th of 1,034
141 · median 78
Started
2025
with 121 others
Phase 2
331 of 1,310
144 open now
Primary completion
2027-06
later than 372 of 557 live
Registered
1,174th of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 350th largest by planned enrollment of the 1,034 interventional ones that give a count, is one of 122 that started in 2025, is one of 331 in phase 2, reaches primary completion later than 372 of the 557 other live ones, and was the 1,174th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until disease progression, intolerable toxicity, start of new anti-tumor therapy, death, patient refuse to continue treatment, loss to follow-up, or other reasons leading to treatment discontinuation. Immediate BICR review is required for patients with radiographic disease progression as assessed by the investigator. If disease progression is assessed by BICR, the investigator is allowed to unblind after disease progression according to the protocol-specified procedures. After unblinding, patients in the experimental arm, study drug should be discontinued. Patients in the control arm may be transferred to receive ABSK-011 plus BSC after assessment.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
  • FGF19 overexpression
  • ABSK-011
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients should understand, sign, and date the written voluntary form prior to any protocol-specific procedures performed. Patients should be able and willing to comply with study visits and procedures as per protocol.
  2. Patients (male or female) ≥ 18 years of age at the time of signing the informed consent form.
  3. Patients with advanced or unresectable HCC confirmed histologically/cytologically or clinically according to the American Association for the Study of Liver Diseases (AASLD) criteria (for patients with cirrhosis).
  4. Have received at least one prior PD- (L) 1 inhibitor approved as a single agent or in combination for the treatment of HCC and at least one mTKI approved for the treatment of HCC.
  5. BCLC stage B(ineligible for local or radical therapy, or relapse or progression of disease after local therapy or radical therapy) or C.
  6. class A.
  7. Positive for FGF19 overexpression.
  8. At least 1 meeting v1.1 criteria.
  9. performance status 0 or 1.
  10. ≥ 3 months.
  11. Adequate control of blood pressure (BP) at screening.
  12. Adequate organ function and bone marrow function.
  13. Non-surgically sterilized male or female patients of must agree to use reliable for at least 2 weeks prior to randomization until 1 month after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known allergies or to any component of the product (ABSK-011 or placebo).
  2. Previous treatment with selective FGFR4 inhibitors.
  3. Known fibrolamellar HCC, sarcomatous HCC, or mixed hepatocellular carcinoma-cholangiocarcinoma.
  4. Previous anti-tumor therapy is ≤ 4 weeks from randomization.
  5. Major surgery within 4 weeks prior to randomization; or any surgical wound infection, dehiscence, or incomplete healing within 2 weeks prior to randomization; Or major surgery is planned during study treatment.
  6. History of second primary other than HCC within the first 5 years of screening.
  7. Liver tumors as a percentage of whole liver ≥ 50% as judged by the investigator.
  8. Toxicities caused by prior chemotherapy, radiotherapy, and other anti-tumor therapies (including immunotherapy) did not recover to ≤ Grade 1 v5.0.
  9. Imaging revealed HCC involving the main portal vein (Vp4), inferior vena cava, superior vena cava, superior mesenteric vein, or heart.
  10. Impaired cardiac function or heart disease.
  11. Patients coinfected with and .
  12. Known acquired immunodeficiency syndrome (AIDS) -associated disease or tested positive for 1/2 antibodies.
  13. Active or documented gastrointestinal bleeding within 6 months prior to screening.
  14. Patients with intractable/uncontrolled pleural or pericardial effusion requiring intervention within 2 weeks prior to randomization and clinically significant ascites.
  15. Prior or current hepatic encephalopathy (any grade).
  16. Presence of meningeal or central nervous system (CNS) .
  17. Previous organ transplant and anti-rejection drug therapy indicated.
  18. The factors that significantly affect the absorption of oral drugs.
  19. Receipt of P-gp transporter inhibitors or moderate, strong inhibitors or inducers of within 2 weeks prior to randomization.
  20. Any serious acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy within 2 weeks prior to randomization.
  21. Patient who cannot be assessed by contrast-enhanced CT and/or MRI due to allergy to computed tomography (CT) and/or magnetic resonance imaging (MRI) contrast media or other .
  22. Any other clinically significant comorbidities may affect the patient's health or safety, affect the signing of , affect protocol compliance, or interfere with the interpretation of the study results.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
141 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    ABSK-011 plus BSC

    Drug: ABSK-011+BSC

  • Placebo comparator
    Control arm

    Placebo plus BSC

    Drug: Placebo+BSC

Interventions

  • DrugABSK-011+BSC

    Drug page: Irpagratinib

    ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

  • DrugPlacebo+BSC

    Placebo capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

06

What researchers measure

Primary outcomes

  1. ORR by BICR

    Objective response rate (ORR) assessed by Blinded Independent Central Review (BICR) per RECIST v1.1, defined as the proportion of patients achieving complete response (CR) or partial response (PR). Patients who receive crossover treatment or start a new anti-tumor therapy prior to achieve an objective response (PR or CR) will be considered as non-responders.

    Time frame: through study completion, up to 2 years

Secondary outcomes

  1. PFS

    Defined as the time (months) from randomization to disease progression or death due to any cause, whichever occurs first.

    Time frame: through study completion, , up to 2 years

  2. DOR

    Defined as the time (months) from the first documented objective response to disease progression or death due to any cause, whichever occurs first.

    Time frame: through study completion, up to 2 years

  3. DCR

    Defined as the proportion of patients achieving CR, PR, or SD (meeting the minimum criteria for SD lasting at least 6 weeks).

    Time frame: through study completion, up to 2 years

  4. TTP

    Defined as the time (months) from randomization to disease progression.

    Time frame: through study completion, up to 2 years

  5. TTR

    Defined as time (months) from randomization to first objective response.

    Time frame: through study completion, up to 2 years

  6. OS

    Defined as the time (months) from randomization to death due to any cause.

    Time frame: through study completion, up to 2 years

  7. ORR by investigator

    Objective response rate (ORR) assessed by the investigator per RECIST v1.1, defined as the proportion of patients achieving complete response (CR) or partial response (PR).

    Time frame: through study completion, up to 2 years

  8. Adverse events

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and incidence of adverse events leading to dose interruption, dose reduction, and discontinuation of study treatment. Eastern Cooperative Oncology Group (ECOG) performance status (PS), laboratory tests, electrocardiogram (ECG), vital signs, and physical examination and changes from baseline.

    Time frame: through study completion, up to 2 years

Other outcomes

  1. Levels of FGF19 in blood samples

    Changes in selected PD markers before and after treatment.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  2. Cmax

    maximum observed concentration

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  3. Tmax

    time to maximum observed concentration

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  4. AUC

    area under the concentration-time curve

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  5. t1/2

    elimination half-life

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  6. Vz/F

    apparent volume of distribution

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  7. CL/F

    apparent oral clearance

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  8. Cmax,ss

    maximum observed concentration of steady-state

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  9. Cmin,ss

    minimum observed concentration of steady-state

    Time frame: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1,Cycle 5 Day 1, End of treatment (each cycle is 28 days)

  10. AUCss

    area under the concentration-time curve of steady-state

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

  11. AR

    accumulation rate

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)

07

Study locations

49 of 51 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Jan 8, 2026
StartActual
Jun 13, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07327034
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Jun 13, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jan 8, 2026

Study contacts

Xiaoping Chen
Contact
chenxpchenxp@163.com
+86-027-83665312
Qi Cheng
Contact
chengqi@hust.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irpagratinib

Start the discussion